NCT04559568

A Study of LY3522348 in Healthy Participants

A Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of Single- and Multiple-Ascending Doses of LY3522348 in Healthy Participants

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 65 (actual)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

The main purpose of this study in healthy participants is to learn more about the safety of LY3522348 and any side effects that might be associated with it. Blood tests will be performed to check how much LY3522348 gets into the bloodstream and how long it takes the body to eliminate it. This study has two parts: Part A will last up to about six weeks and Part B will last up to about eight weeks for each participant.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	LY3522348	Administered orally.
DRUG	Placebo	Administered orally.
DRUG	Midazolam	Administered orally.

Timeline

• Start date: 2020-10-15
• Primary completion: 2021-08-17
• Completion: 2021-08-17
• First posted: 2020-09-23
• Last updated: 2025-11-04
• Results posted: 2025-11-04

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study